UNIVERSITY *of* York

This is a repository copy of *Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease patients treated according to contemporary evidence based medicine:Update of the Cardiac Rehabilitation Outcome Study (CROS-II)*.

White Rose Research Online URL for this paper:
https://eprints.whiterose.ac.uk/id/eprint/157898/

Version: Accepted Version

Article:

White Rose
university consortium
Universities of Leeds, Sheffield & York

eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/

1 Effectiveness of Comprehensive Cardiac Rehabilitation in Coronary Artery Disease Patients Treated According to

2 Contemporary Evidence Based Medicine – Update of the Cardiac Rehabilitation Outcome Study (CROS-II)

3 Annett Salzwedel1, Katrin Jensen2, Bernhard Rauch3, Patrick Doherty4, Maria-Inti Metzendorf5, Matthes

4 Hackbusch2, Heinz Völler1, Jean-Paul Schmid6 and Constantinos H Davos7; on behalf of the 'Cardiac Rehabilitation

5 Section', European Association of Preventive Cardiology (EAPC), in cooperation with the Institute of Medical

6 Biometry and Informatics (IMBI), Department of Medical Biometry, University of Heidelberg, and the Cochrane

7 Metabolic and Endocrine Disorders Group, Institute of General Practice, Heinrich-Heine University, Düsseldorf,

8 Germany

9

10 1Department of Rehabilitation Research, University of Potsdam, Germany

11 2Institute of Medical Biometry and Informatics (IMBI), University of Heidelberg, Germany

12 3Institut für Herzinfarktforschung Ludwigshafen, Germany

13 4Department of Health Sciences, University of York, UK

14 5Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice (ifam), Medical Faculty, Heinrich

15 Heine University Düsseldorf, Germany

16 6Department of Cardiology, Clinic Barmelweid, Switzerland

17 7Cardiovascular Research Laboratory, Biomedical Research Foundation, Academy of Athens, Greece

18

19 Corresponding author:

20 Constantinos H Davos, Cardiovascular Research Laboratory, Biomedical Research Foundation, Academy of Athens, 4

21 Soranou Ephessiou Street, 11527 Athens, Greece

22 Email: cdavos@bioacademy.gr

23 Word count: 7080 (4 Tables and 2 Figures)

24

Abstract

Background: Despite numerous studies and meta-analyses the prognostic effect of cardiac rehabilitation (CR) is still under debate. This update of the Cardiac Rehabilitation Outcome Study (CROS II) provides a contemporary and practice focused approach including only CR interventions based on published standards and core components to evaluate CR delivery and effectiveness in improving patient`s prognosis.

Design: Systematic review and meta-analysis

Methods: Randomized controlled trials (RCT) and retrospective and prospective controlled cohort studies (rCCS, pCCS) evaluating patients after acute coronary syndrome (ACS), coronary bypass grafting (CABG) or mixed populations with coronary artery disease (CAD) published until Sep 2018 were included.

Results: Based on CROS inclusion criteria out of 7,096 abstracts 6 additional studies including 8,671 patients were identified (2 RCT, 2 rCCS; 2 pCCS). In total, 31 studies including n=228,337 patients were available for this meta-analysis (3 RCT, 9 pCCS, 19 rCCS; patients after ACS: n=50,653, after CABG: n=14,583, mixed CAD populations: n=163,101; follow-up periods ranging from 9 months up to 14 years).

Heterogeneity in design, CR delivery, biometrical assessment and potential confounders was considerable. CCS showed a significantly reduced total mortality (primary endpoint) after CR participation in patients after ACS [pCCS: hazard ratio (HR) 0.37, 95% confidence interval (CI): 0.20-0.69; rCCS: HR 0.64, 95% CI 0.53-0.76; pCCS: odds ratio (OR) 0.20, 95% CI 0.08-0.48], but the single RCT fulfilling the CROS inclusion criteria showed neutral results. CR participation also was associated with reduced total mortality in patients after CABG (rCCS: HR 0.62, 95% CI 0.54-0.70, one single RCT without fatal events), and in mixed CAD populations (rCCS: HR 0.52, 95% CI 0.36-0.77; 2 out of 10 CCS with neutral results).

Conclusion: CROS II confirms the effectiveness of CR participation after ACS and after CABG in actual clinical practice by reducing total mortality under the conditions of current evidence-based CAD treatment. The data of CROS II, however, underscore the urgent need to define internationally accepted minimal standards for CR delivery as well as for scientific evaluation.

Word count: 325

Introduction

Within the past 25 years, cardiovascular morbidity and mortality after acute coronary syndromes (ACS) showed remarkable decrease which is associated with the implementation of acute coronary revascularizations as well as the application of effective acute and long-term pharmacotherapy.[1] Supporting these results from the United States[1] the French FAST-MI registry revealed a mortality reduction six months after ST-elevation myocardial infarction (STEMI) and Non-ST-elevation myocardial infarction (NSTEMI) from 17.2% to 5.3% and 6.3% respectively.[2] Moreover, on the basis of the SWEDEHEART registry a marked improvement of 2-years survival was found, but strictly associated with the use of acute coronary interventions and evidence-based long-term secondary prevention.[3] Accordingly, current evidence-based treatment modalities of ACS and CAD do have a large impact on acute and long-term success of care delivered to these patients. Against this background the effects of special treatment modalities like cardiac rehabilitation (CR) need to be re-evaluated in light of their added short and long-term clinical and prognostic benefit. The Cardiac Rehabilitation Outcome Study (CROS) aimed to evaluate the prognostic effect of CR after ACS and coronary artery bypass grafting (CABG) in the modern era of cardiovascular treatment modalities. On the basis of predominantly controlled observational studies including a large amount of patients, CROS confirmed a beneficial effect of CR (i.e. reduced all cause mortality after ACS and after CABG).[4] However, with CROS it became apparent that minimal requirements for CR delivery (based on published standards and core components)[5–8] had to be fulfilled to reach effectiveness. These minimal requirements have been addressed by other recent meta-analyses[9–13] with a focus on volume and intensity of exercise sessions and treatment of CV risk factors during CR. Not meeting these minimal requirements may explain in part the negative results of some recent studies and meta-analyses.[14–16]

Against this background, the aim of this CROS-update was to critically re-evaluate the results of CROS I in the light of newly published CR studies meeting the strict CROS inclusion criteria. Moreover, the aim of this update was to further elucidate the CR-effect on secondary and non-fatal clinical endpoints representing a heterogeneous field in clinical CR research. By evaluating controlled observational studies the CROS data finally reflect everyday clinical care thereby allowing an estimation of how guideline standards are actually translated into clinical practice.

78 Methods

79 This review was conducted and reported according to the PRISMA statement (Preferred Reporting Items for

80 Systematic Reviews and Meta-Analyses), and the MOOSE statement (Meta-analysis Of Observational Studies

81 in Epidemiology).[17,18] The core methods used were essentially unchanged compared to the 2016

82 publication. The study protocol was prospectively published in PROSPERO (CRD42014007084).[19]

83 Study eligibility criteria

84 Randomized controlled trials (RCT) as well as prospective and retrospective controlled cohort studies (pCCS,

85 rCCS) of multi-component CR versus usual care, with a follow-up period of at least six months, were

86 investigated. We included men and women of all ages after hospitalization for ACS or CABG, respectively. In

87 addition, we included studies enrolling mixed populations of patients after ACS and/or after CABG as basic

88 requirement, as well as patients with chronic stable coronary artery disease (CAD) with or without elective

89 percutaneous coronary intervention (PCI). Patient enrolment had to be carried out by 1995 or later. The

90 primary endpoint was total mortality. Secondary endpoints mainly included non-fatal cardiovascular events,

91 hospital readmissions and mixed endpoints. The detailed study selection criteria were previously presented

92 (see LINK TO SUPPLEMENTAL MATERIAL, Table SM 1).[4]

93 Search methods and identification of studies

94 For the previous review[4] highly sensitive search strategies were developed to identify two types of studies:

95 RCT and CCS regardless of the studies´ current status (published, unpublished, finished or ongoing). A

96 detailed description of the elaboration of the search strategy is available in the previous review.[4]

97 For this update, we restricted our search to the following four databases: PubMed, Embase, Cochrane

98 Central Register of Controlled Trials and the World Health Organization´s International Clinical Trials Registry

99 Platform (ICTRP). Databases, which did not contribute studies for inclusion in the previous review, were no

100 longer deployed. The search informing this update comprised the period 23 December 2015 – 4 September

101 2018. No language restrictions were applied. Details of all search strategies are documented in supplemental

102 material (LINK TO SUPPLEMENTAL MATERIAL, Table SM 2). In addition to searching electronic databases, the

103 references of recent systematic reviews were screened.

104 Study selection

105 The titles and abstracts of all references were independently evaluated by at least two members of the

106 reference selection board (AS, CHD, BR). Abstracts of potential interest were re-evaluated and selected for

107 full text evaluation (FTE) and structured study evaluation (SSE), respectively, consented within the whole

108 board. FTE for assessing main inclusion criteria and SSE with quality assessment was performed and

109 consented within an extended reference selection board (AS, CHD, BR, PD) including a biometrician (KJ). The

110 primary reasons for study exclusion are given in Table SM 4 (online version, supplemental material).

111 For the meta-analysis, the studies resulting from the SSE process of the current update were merged with

112 the selected studies from the 2016 publication. The study selection process is outlined in Figure 1.

113 Study evaluation process

114 The study evaluation included design, data sources, information on population, interventions, controls,

115 calculation and presentation of outcomes and handling of bias. For RCT the Cochrane risk of bias table

116 (http://tech.cochrane.org/revman/download), and for the CCS the checklists of methodological issues on

117 non-randomized studies,20,21 and the Newcastle Ottawa Scale (NOS) were used.22 To facilitate the study

118 evaluation with respect to management of confounding, age, gender, smoking, diabetes, history of stroke,

119 history of acute myocardial infarction (AMI), reduced left ventricular ejection fraction and acute or early PCI

120 during AMI have been pre-specified as potential confounders.

121 Data extraction

122 Data extraction was performed by two biometricians independently (KJ, MH), using a standardized

123 extraction form. Disagreements were solved by consensus. We extracted the following information from

124 each eligible article: name of first author, year of publication, study location (country), study design, data

125 source, number of participants, population (ACS, CABG or mixed), inclusion period, inclusion criteria, follow-

126 up time, mean age of participants, proportion of men, intervention characteristics, control characteristics,

127 reported outcomes, information on outcomes, data on outcomes, covariates included in the adjusted

128 models.

129 Statistical analysis

130 The analyses were separated with regard to population (AMI, CABG or mixed) and study design (RCT,

131 pCCSand rCCS). For time-to-event outcomes, the hazard ratio (HR) with its 95% confidence interval was

132 chosen as effect measure per study. If possible, log HRs and their standard errors were extracted directly,

133 preferably from an adjusted model and matched-group analysis. If they were not reported but adequate

134 univariate analyses were available, an indirect estimation method was used.23,24 In some study

135 publications, instead of HR adjusted odds ratios (OR) at the end of follow-up or only absolute numbers of

136 events to calculate ORs were reported. HRs and ORs were reported and pooled separately in the present

137 review.25 For dichotomous outcomes, the OR with its 95% confidence interval was used as the effect

138 measure per study. If no event occured in one or in both arms, a continuity correction of 0.5 per cell was

139 applied. For consistency, we re-calculated the treatment effect to be in the same direction, as necessary,

140 with an HR or OR above 1 indicating a higher risk for CR with respect to each outcome. HRs were combined

141 using the generic inverse-variance method. ORs were pooled using the Mantel-Haenszel method or the

142 generic inverse-variance method. The latter one was used when at least one study reported an adjusted OR.

143 Random-effects models were used to calculate overall effect estimates and confidence intervals because we

144 assumed heterogeneity between the 'true' effects of the different CR programs used in the studies. All

145 results were investigated for statistical heterogeneity by I2 statistics with 0-30% representing no or only

146 small, 30-60% moderate, 50-90% substantial and 75-100% considerable heterogeneity.26 A statistical

147 investigation of potential publication bias based on a test of funnel plot asymmetry could not be done

148 because of too few studies per single meta-analysis.26 Nevertheless, sensitivity analyses for the outcome

149 total mortality have been performed with respect to extracted results of alternative analysis techniques (e.g.

150   independent groups instead of matched groups). There are some deviations from the review protocol

151   published in PROSPERO.19 ORs instead of RRs were used as effect measure for dichotomous outcomes

152   because in some studies adjusted ORs and no absolute numbers are reported. Furthermore, it was not

153   possible to undertake the planned subgroup analyses due to the small number of studies in each subgroup.

154   R version 3.5.1 (R Foundation for Statistical Computing, 2015) and the R "meta" package version 4.9-2

155   (developed by Guido Schwarzer) was used for all statistical analyses.

156   Results

157   Study characteristics

158   Study characteristics (design, population, interventions, controls and primary results) of the newly identified

159   studies are presented in Table 1. With respect to the design, only 2 RCT (n=240 patients) fulfilled the CROS

160   criteria increasing the total number of RCT to 3 (n=2,053 patients). In addition, 2 rCCS (n=5,238 patients) and

161   2 pCCS (n=3,193 patients) were newly identified. Thus, a total of 18 rCCS (n=211,334 patients) and 9 pCCS

162   (n=15,386 patients) were considered for final analysis.

163   Three new studies enrolled 4,315 patients after ACS (total of 15 studies; n=50,653 patients), one additional

164   study included 36 patients after CABG (total of 10 studies; n=14,583 patients), while 2 newly identified

165   studies recruited 4,320 patients in "mixed populations" (total of 11 studies; n=163,101 patients).

166   CR setting was "out-patient" in all new studies (total of 27) and CR duration varied from 12 weeks to 12

167   months, thereby not changing the range of 3-4 weeks up to 12 months identified in the previous CROS study.

168   Moreover, the previously reported "CR intensity" ranging from 2 up to more than 5 exercise sessions per

169   week plus motivation, information, education, and psychosocial interventions with variable intensities and

170   combinations remained unchanged.

171   Notably, the included studies reveal a considerable heterogeneity not only with respect to the predefined

172   study designs (RCT, pCCS, rCCS), and populations (after ACS, after CABG, mixed CAD populations), but also

173   with respect to study endpoints and biometrical evaluation (Tables 2, 3a/b and Fig. 2). For this reason, the

174   majority of the secondary endpoints predefined by CROS could not be integrated into a meta-analysis (Table

175   2, Figure 2).

176   Primary endpoint "total mortality"

177   A summary of the clinical outcomes is shown in Table 2. The primary endpoint "total mortality" was

178   evaluated in 27 studies, one of them evaluating both, mortality after ACS and after CABG (Figure 2).[27]

179   Participation in CR was associated with a significant reduction of total mortality in all but 6 studies.[14,28–32]

180   After ACS a significant reduction of total mortality was confirmed by the newly added pCCS (4 studies, HR

181   0.37, 95% CI 0.20-0.69; I^2=28%) and even strengthened by the newly added rCCS (4 studies; HR 0.64, 95% CI

182   0.53-0.76; I2=33%).

183   After CABG, the newly identified single RCT was small, only enrolling n=36 low risk patients. During a follow-

184   up period of one year, no deaths occurred, and the risk of "underpowering" has to be regarded as high in

185   this study (see Table 3b, Figure 2).. No additional rCCS or pCCS were identified; consequently, the previous

186   positive results on mortality reduction remained unchanged in this population.

187   In "mixed populations" the addition of one more pCCS confirmed the significant mortality reduction in CR

188   participants (2 studies; HR 0.66, 95% CI 0.55-0.79) with zero heterogeneity. No additional rCCS calculating

189   HR within the mixed populations could be included by the current search (HR 0.52, 95% CI 0.36-0.77, I^2=84%).

190   The single rCCS newly added within the group calculating OR did not change the neutral result reported

191   before in this group (3 studies, OR 0.68, 95% CI 0.34-1.37) but heterogeneity was high (I2=94%). Sensitivity

192   analyses did not change the overall results.

193   Secondary endpoints

194   The results of CROS II with respect to the secondary endpoints are listed in Table 2, differentiating between

195   the various study designs, populations and biometrical approaches. These results are summarized as follows:

Regarding the secondary endpoints "CV mortality" (3 additional studies, 7 studies in total) and "MACCE" (3 studies, unchanged) all selected studies considerably differed with respect to populations and designs, and a "matching" of these studies for meta-analysis was not possible (Table 2). Focusing on the endpoint "CV mortality" and based on the two large controlled observational studies (pCCS, rCCS) there might be a trend in favor of CR participation after ACS and after CABG. With regard to the endpoint MACCE, however, the selected studies do not allow a final conclusion on the effect of CR-participation (Table 2).

The outcomes "non-fatal MI" (total 7 studies) and "non-fatal stroke" (total 3 studies) also did not show a clear trend, but all studies varied in design and population thus hindering a further evaluation by meta-analysis.

The same is true for studies investigating the variably predefined endpoints for "hospital readmission" (endpoints 6-9, see Methods). Most of these studies had heterogeneous designs, and matching of the studies for meta-analysis was not possible (Table 2).

In a descriptive way the results on "hospital readmission" may be summarized as follows: all studies included in CROS either showed a reduction of hospital readmissions in favor of CR-participation, or there was a neutral result. In 12 studies, combined endpoints with various components were evaluated. One more RCT has been identified showing a statistically reduced combined end-point (death, recurrent acute coronary events, or hospitalization for HF) after CR participation compared to usual care (HR=0.26, 95% CI 0.09–0.73).[33]

Quality evaluation of the studies:

The sum of positive adjudications estimated by NOS is presented in Table 3a (for details see online version, supplemental material: Table SM 5). Four additional studies were graded within a range of 5-7. In total, 5 out of 28 studies (18%) were graded with 5 points or less. Limitations were found with respect to representativeness (6 studies), comparability of the cohorts (3 studies), adequacy of follow-up (5 studies), and the assessment of outcomes (2 studies).

On the basis of the checklist of methodological issues on non-randomized studies the following limitations were identified (Tables 3a/b):

Three studies were based on a secondary analysis of original studies with different original objectives

In 3 studies, either time or location differences between the study groups were apparent.

In most studies, the group formation was potentially influenced by health care decision makers and patient's preferences.

The majority of the studies had unclear study protocols and a consort flow diagram was presented only in seven out of 28 studies

Management of confounding was not reported in 3 studies, whereas the description of potential confounding domains remained unclear or has not been reported in 16 studies.

Predefinition and calculation of all confounding domains as pre-specified by CROS (see Materials and Methods) were performed to various degrees. In only 4 studies all 8 predefined confounders were considered for adjustment. Moreover, 6 studies only considered 3 or even less confounders as predefined by CROS. In general, adjustment for confounding was performed in 24 CCS with 4 studies not applying adequate biometrical methods.

BothRCT evaluating the primary endpoint "total mortality" do have a considerable risk of being underpowered (Table 3b).[14,30,33]

Discussion

This update of the Cardiac Rehabilitation Outcome Study (CROS II) confirms the beneficial prognostic effect of CR in CAD patients by significantly reducing the primary endpoint "total mortality" especially after ACS or CABG. However, the effects of CR-participation on secondary endpoints like "CV-mortality", "non fatal myocardial infarction", "non fatal stroke", "combined endpoints" and various forms of "hospital

243 readmission" remain less clear. This at least in part - is due to a considerable heterogeneity of the selected

244 studies with respect to design, populations, predefined endpoints and biometry. Inconsistent results may be

245 due to the kind of selected endpoints including "weak" endpoints with increased risks of confounding. This

246 is particularly true for the variable forms of "hospital re-admission", which may be influenced by local

247 routines in medical services, individual comorbidities not necessarily associated with CV diseases, and the

248 individual`s disease perception. Moreover, a longer survival of patients after AMI/CABG may reveal other

249 diseases that primarily determine the number of hospital admissions during prolonged follow-up.

250 With regard to the secondary endpoint "non-fatal AMI" an overall "neutral" effect also has been reported

251 by Cochrane (Anderson et al. 2016). As AMI and death are closely interrelated clinical events one might

252 speculate that CR-participation effectively prevents death initiated by AMI, but also reduces the incidence

253 of AMI (fatal + non-fatal) per se, resulting in an apparent "neutral effect" with respect to non-fatal AMI

254 occurrence. Unfortunately, the data sources presently available for CROS do not allow to further evaluate

255 this hypothesis.

256 One of the major strengths of this study is its robust approach to CR intervention aligned with published

257 national CR standards and core components.[5–7] Our strict definition of a comprehensive multi-component

258 CR underscores the importance of the amount of physical exercise provided, the adherence to exercise

259 intervention and the adherence to non-exercise components on the patients' prognosis. The results of

260 recently published meta-analyses (some of them including studies of the modern era of novel medication

261 and interventions) seem to support this approach and somehow elucidate our results. Thus, van Halewijn et

262 al. have shown that a significant reduction in all-cause mortality was feasible in CAD patients only under the

263 condition of a comprehensive CR program managing six or more CV risk factors,[10] while the recently

264 published EU-CaRE study showed positive effects of comprehensive CR in 58% of older patients with three

265 or more uncontrolled risk factors before CR.[34] These findings, coupled with CROS II results, strengthen

266 clinical recommendations that comprehensive CR is preferable to standalone exercise based CR in reducing

267 total and cardiac mortality, in post-MI patients.[13] The effectiveness of a comprehensive CR program is

268 increased by the patient's adherence and by the shared effort to consequently assess and treat the majority

269 of all individual CV risk factors.

270 With regards to the importance of the CR dose, Santiago de Araujo Pio et al. established that total mortality

271 reduction was only possible in cardiovascular disease patients experiencing medium and high doses of CR.[12]

272 Similar CR dose and volume related effects on mortality have been published.[9,35] Finally, in a systematic

273 review of multi-component CR, applying almost all CROS inclusion criteria, the study by Sumner et al. carried

274 out a meta-analysis of observational studies published after the year 2000, concluding that all-cause and

275 cardiac mortality were reduced in AMI patients following a CR program.[36]

276 Still, one has to keep in mind that this beneficial effect of CR-participation as shown in CROS may not apply

277 to special subgroups like elderly and frail patients who need a particularly personalized approach.[37]

278 According to Deaton C et al.[38] however, the average age of the CROS study population reflects actual clinical

279 reality. Likewise, CR participation of patients with severe systolic heart failure may not result in mortality

280 reduction as shown in previous meta-analyses.[39–41]

281 Apart from these limitations, CROS II presents a timely account of the effectiveness of CR when delivered to

282 agreed published standards including scientifically proven CR core components.[5–7] Utilizing a strict

283 approach to CR intervention study inclusion we can report a significant benefit (Table 2 and figure 2) in favor

284 of CR with respect to all-cause mortality. However, at the same time this approach might be viewed as a

285 significant weakness as it makes our findings almost incompatible with previous reviews which have been

286 much more inclusive of CR interventions often defined by innovations in CR being evaluated as part of clinical

287 trials rather than informed by interventions based on published CR program standards and core

288 components. Only three RCT were selected for CROS II compared to 63 in the most recent Cochrane review

289 which reported a significant reduction in cardiovascular mortality but not in all-cause mortality.[9] We are not

290 suggesting that previous trial based reviews are erroneous. On the contrary, we agree that robust trials-

291 based reviews remain top of the evidence base hierarchy. What we are prosing is that, the CROS II approach

292 differs to the extent that it should be viewed as an additional form of evidence that utilizes registry-based

293 research reflecting a broader population in the modern cardiology era from 1995 onwards.

294 For a critical estimation of the CROS II results, the following aspects have to be emphasized:

295 Cardiac rehabilitation participation after ACS or CABG is associated with reduced total mortality if delivered

296 on top of the current evidence-based treatment modalities (medication and acute coronary interventions).

297 Cardiac rehabilitation participation therefore may contribute to treatment adherence and further add

298 effective individual life style changes necessary to significantly reduce patient`s cardiovascular risk.[42–46]

299 This positive effect of CR participation obviously works in current clinical practice of different countries

300 provided a minimum of CR volume and intensity is delivered. This especially refers to the individually adapted

301 and supervised exercise training and a rigorous treatment of all individual cardiovascular risk factors.

302 [9,12,13,47]

303 Unfortunately, these prerequisites of successfully delivered CR - although outlined in detail in many position

304 papers - are not necessarily followed in clinical practice. As noted in CROS II, these prerequisites are not

305 sufficiently described in many clinical studies evaluating CR effectiveness. Therefore, there is an urgent need

306 to effectively translate these well-known and evidence-based minimal standards into all day clinical practice

307 wherever CR is offered. Moreover, these clinical standards need to be the adamant basis of future CR

308 outcome studies. To this end, minimal standards for CR interventions in clinical practice and clinical trials

309 should be based on robust published guidelines and research. We offer the CROS II definition and criteria as

310 a useful guide for optimal CR intervention content and delivery; including multi-disciplinary and multi-

311 component programs with structured, supervised exercise training delivered at least twice per week in

312 combination with motivational techniques, risk factor modification education, dietary advices, psychosocial

313 and vocational support delivered at least once per week. The CR setting could be in-, out-patient or mixed

314 but the time between hospital discharge and CR initiation should be as low as possible, preferably within

315 three months.

316 From this background it is one of the CROS study's aim not only to evaluate the results and clinical outcomes

317 of the studies included, but also to critically evaluate strengths and deficiencies in detail of each single study

318 included into the meta-analysis (see Table 3). As in the first evaluation in CROS, this update uncovers

319 considerable deficits in current CR studies that need to be addressed and prevented in future. These deficits

320 include predominantly insufficient description of CR content (e.g. applied components), frequency and

321 volume of exercise sessions, CR initiation (i.e. after hospital stay for an acute cardiac event) and duration,

322 absence of CR adherence at follow up as well as methodological issues such as the inadequate consideration

323 of confounding parameters at the stage of study and statistical analysis design.

324 **Clinical implications**

325 Together with the results of other recent reviews, minimal requirements for a successful CR after ACS or

326 CABG are apparent and need to be ensured in clinical practice:[4,9,10,12,13,45]

327 - Cardiac rehabilitation is multi-component including consequent treatment of the individual`s

328   cardiovascular risk factors, individually adapted physical exercise, information, motivation as well as

329   individualized psychosocial support.[4]

330 - The individualized approach also reflects gender, age, frailty, heart failure, concomitant diseases,

331   psychosocial background and effectors of the individual`s health and capabilities.

332 - Cardiac rehabilitation is supervised and carried out by adequately trained health professionals

333   including cardiologists.[4]

334 - During CR the "dose" of exercise training (number of weeks of exercise training × average number of

335   sessions/week × average duration of session in minutes) exceeds 1.000.[9]

336 - The number of CR sessions (including physical exercise, information, education and psychosocial

337   support) needs to exceed 36.[12]

338 - During CR all individually recognized cardiovascular risk factors need to be addressed and treated.[10]

339   Consequently, future studies on the effect of CR need to report in detail whether these minimal

340   requirements were rigorously followed by the participating CR centres.

341   **Conclusions**

342   CROS II confirms the effectiveness of CR participation after ACS and after CABG in actual clinical practice by reducing

343   total mortality under the conditions of current evidence-based CAD treatment. The CROS approach to more strictly

344   predefined CR intervention and to include controlled registry based studies represents a valid hybrid approach that

345   has clear utility in clinical decision-making.

Systematic review registration

Previous review version

Declaration of conflicting interests

Funding

Author contribution

All authors participated in designing the study, generating hypotheses, interpreting data, and critically reviewing the report. The special responsibilities were as follows:

Initiation, organization and leading of the project: BR, CHD, PD, JPS, HV; literature search and search strategies: MIM, BR; study selection: AS, CHD, PD, BR; study evaluation: AS, CHD, BR, KJ; statistical and biometrical analyses: KJ, MH; writing: AS, HV, CHD, PD, KJ, MIM, BR; internal reviewing: JPS, BR, HV, AS, PD, CHD, and the nucleus members of the Secondary Prevention and Rehabilitation section of the European Association of Preventive Cardiology (EAPC).

References

1. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007; 356: 2388–2398.

394   2.   Puymirat E, Simon T, Cayla G, et al. Acute Myocardial Infarction: Changes in Patient Characteristics,
395   Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry
396   of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015. Circulation 2017; 136:
397   1908–1919.

398   3.   Szummer K, Wallentin L, Lindhagen L, et al. Relations between implementation of new treatments and
399   improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years:
400   experiences from SWEDEHEART registry 1995 to 2014. European Heart Journal 2018; 39: 3766–3776.

401   4.   Rauch B, Davos CH, Doherty P, et al. The prognostic effect of cardiac rehabilitation in the era of acute
402   revascularisation and statin therapy: A systematic review and meta-analysis of randomized and non-
403   randomized studies - The Cardiac Rehabilitation Outcome Study (CROS). European journal of preventive
404   cardiology 2016; 23: 1914–1939.

405   5.   Piepoli MF, Corra U, Adamopoulos S, et al. Secondary prevention in the clinical management of patients
406   with cardiovascular diseases. Core components, standards and outcome measures for referral and
407   delivery: a policy statement from the cardiac rehabilitation section of the European Association for
408   Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the
409   European Society of Cardiology. European journal of preventive cardiology 2014; 21: 664–681.

410   6.   Cowie A, Buckley J, Doherty P, et al. Standards and core components for cardiovascular disease
411   prevention and rehabilitation. Heart (British Cardiac Society) 2019; 105: 510–515.

412   7.   Balady GJ, Williams MA, Ades PA, et al. Core components of cardiac rehabilitation/secondary prevention
413   programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac
414   Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on
415   Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism;
416   and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation 2007; 115:
417   2675–2682.

418   8.   Taylor RS, Anderson L, Oldridge N, et al. The Efficacy of Exercise-Based Cardiac Rehabilitation: The
419   Changing Face of Usual Care. Journal of the American College of Cardiology 2017; 69: 1207–1208.

420   9.   Anderson L, Thompson DR, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart
421   disease. The Cochrane database of systematic reviews 2016: Cd001800.

422   10. van Halewijn G, Deckers J, Tay HY, et al. Lessons from contemporary trials of cardiovascular prevention
423   and rehabilitation: A systematic review and meta-analysis. International Journal of Cardiology 2017; 232:
424   294–303.

11. Almodhy M, Ingle L and Sandercock GR. Effects of exercise-based cardiac rehabilitation on cardiorespiratory fitness: A meta-analysis of UK studies. International journal of cardiology 2016; 221: 644–651.

12. Santiago de Araujo Pio C, Marzolini S, Pakosh M, et al. Effect of Cardiac Rehabilitation Dose on Mortality and Morbidity: A Systematic Review and Meta-regression Analysis. Mayo Clinic proceedings 2017; 92: 1644–1659.

13. Lawler PR, Filion KB and Eisenberg MJ. Efficacy of exercise-based cardiac rehabilitation post-myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. American Heart Journal 2011; 162: 571-584.e2.

14. West RR, Jones DA and Henderson AH. Rehabilitation after myocardial infarction trial (RAMIT): multi-centre randomised controlled trial of comprehensive cardiac rehabilitation in patients following acute myocardial infarction. Heart (British Cardiac Society) 2012; 98: 637–644.

15. Powell R, McGregor G, Ennis S, et al. Is exercise-based cardiac rehabilitation effective?: A systematic review and meta-analysis to re-examine the evidence. BMJ open 2018; 8: e019656.

16. Blokzijl F, Dieperink W, Keus F, et al. Cardiac rehabilitation for patients having cardiac surgery: a systematic review. J Cardiovasc Surg (Torino) 2018.

17. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews 2015; 4: 1.

18. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283: 2008–2012.

19. Rauch B, Doherty P, Schmid J-P, et al. The prognostic effect of cardiac rehabilitation in the era of acute revascularization and statin therapy: a systematic review and meta-analysis of randomized and non-randomized studies. The Cardiac Rehabilitation Outcome Study (CROS). PROSPERO 2014 CRD42014007084, https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=7084 (2014, accessed 15 October 2019).

20. Wells GA, Shea B, Higgins JPT, et al. Checklists of methodological issues for review authors to consider when including non-randomized studies in systematic reviews. Research Synthesis Methods 2013; 4: 63–77.

21. Higgins JPT, Ramsay C, Reeves BC, et al. Issues relating to study design and risk of bias when including non-randomized studies in systematic reviews on the effects of interventions. Research Synthesis Methods 2013; 4: 12–25.

456 22. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of
457 nonrandomised studies in meta-analyses,
458 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (2008, accessed 20 May 2019).

459 23. Parmar MK, Torri V and Stewart L. Extracting summary statistics to perform meta-analyses of the
460 published literature for survival endpoints. Statistics in medicine 1998; 17: 2815–2834.

461 24. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data
462 into meta-analysis. Trials 2007; 8: 16.

463 25. Symons MJ and Moore DT. Hazard rate ratio and prospective epidemiological studies. Journal of Clinical
464 Epidemiology 2002; 55: 893–899.

465 26. Higgins JPT and Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0
466 [updated March 2011], http://handbook.cochrane.org (2011).

467 27. Vries H de, Kemps HMC, van Engen-Verheul MM, et al. Cardiac rehabilitation and survival in a large
468 representative community cohort of Dutch patients. European Heart Journal 2015; 36: 1519–1528.

469 28. Kim C, Kim DY and Moon CJ. Prognostic influences of cardiac rehabilitation in korean acute myocardial
470 infarction patients. Annals of rehabilitation medicine 2011; 35: 375–380.

471 29. Meurs M, Burger H, van Riezen J, et al. The association between cardiac rehabilitation and mortality risk
472 for myocardial infarction patients with and without depressive symptoms. J Affect Disord 2015; 188: 278–
473 283.

474 30. Aronov DM, Bubnova MG, Ioseliani DG, et al. The Complex Program of Rehabilitation of Patients With
475 Ischemic Heart Disease After Coronary Artery Bypass Surgery in Ambulatory Cardiorehabilitational
476 Department: Clinical Effects of Third Stage of Rehabilitation. Kardiologiia 2017; 57: 10–19.

477 31. Schwaab B, Waldmann A, Katalinic A, et al. In-patient cardiac rehabilitation versus medical care - a
478 prospective multicentre controlled 12 months follow-up in patients with coronary heart disease.
479 European journal of cardiovascular prevention and rehabilitation official journal of the European Society
480 of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise
481 Physiology 2011; 18: 581–586.

482 32. Doimo S, Fabris E, Piepoli M, et al. Impact of ambulatory cardiac rehabilitation on cardiovascular
483 outcomes: a long-term follow-up study. European Heart Journal 2019; 40: 678–685.

484 33. Hautala AJ, Kiviniemi AM, Makikallio T, et al. Economic evaluation of exercise-based cardiac rehabilitation
485 in patients with a recent acute coronary syndrome. Scandinavian journal of medicine & science in sports
486 2017; 27: 1395–1403.

487   34. Prescott E, Mikkelsen N, Holdgaard A, et al. Cardiac rehabilitation in the elderly patient in eight
488   rehabilitation units in Western Europe: Baseline data from the EU-CaRE multicentre observational study.
489   European Journal of Preventive Cardiology 2019; 26: 1052–1063.

490   35. Abell B, Glasziou P and Hoffmann T. The Contribution of Individual Exercise Training Components to
491   Clinical Outcomes in Randomised Controlled Trials of Cardiac Rehabilitation: A Systematic Review and
492   Meta-regression. Sports medicine - open 2017; 3: 19.

493   36. Sumner J, Harrison A and Doherty P. The effectiveness of modern cardiac rehabilitation: A systematic
494   review of recent observational studies in non-attenders versus attenders. PloS one 2017; 12: e0177658.

495   37. Vigorito C, Abreu A, Ambrosetti M, et al. Frailty and cardiac rehabilitation: A call to action from the EAPC
496   Cardiac Rehabilitation Section. European journal of preventive cardiology 2017; 24: 577–590.

497   38. Deaton C. Addressing the paradox of age and participation in cardiac rehabilitation. European Journal of
498   Preventive Cardiology 2019; 26: 1050–1051.

499   39. Bjarnason-Wehrens B, Nebel R, Jensen K, et al. Exercise-based cardiac rehabilitation in patients with
500   reduced left ventricular ejection fraction: The Cardiac Rehabilitation Outcome Study in Heart Failure
501   (CROS-HF): A systematic review and meta-analysis. European Journal of Preventive Cardiology 2019:
502   2047487319854140.

503   40. Taylor RS, Long L, Mordi IR, et al. Exercise-Based Rehabilitation for Heart Failure: Cochrane Systematic
504   Review, Meta-Analysis, and Trial Sequential Analysis. JACC Heart Fail 2019; 7: 691–705.

505   41. Taylor RS, Walker S, Smart NA, et al. Impact of exercise-based cardiac rehabilitation in patients with heart
506   failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of
507   randomised trials. European Journal of Heart Failure 2018; 20: 1735–1743.

508   42. Hammill BG, Curtis LH, Schulman KA, et al. Relationship Between Cardiac Rehabilitation and Long-Term
509   Risks of Death and Myocardial Infarction Among Elderly Medicare Beneficiaries. Circulation 2010; 121:
510   63–70.

511   43. Kavanagh T, Mertens DJ, Hamm LF, et al. Peak oxygen intake and cardiac mortality in women referred
512   for cardiac rehabilitation. J. Am. Coll. Cardiol. 2003; 42: 2139–2143.

513   44. Martin BJ, Arena R, Haykowsky M, et al. Cardiovascular fitness and mortality after contemporary cardiac
514   rehabilitation. Mayo Clinic Proceedings 2013; Mayo Clinic. 88: 455–463.

515   45. Dibben GO, Dalal HM, Taylor RS, et al. Cardiac rehabilitation and physical activity: systematic review and
516   meta-analysis. Heart (British Cardiac Society) 2018; 104: 1394–1402.

517   46. Janssen V, Gucht V de, Dusseldorp E, et al. Lifestyle modification programmes for patients with coronary
518   heart disease: a systematic review and meta-analysis of randomized controlled trials. European Journal
519   of Preventive Cardiology 2013; 20: 620–640.

47. Kavanagh T, Hamm LF, Beyene J, et al. Usefulness of improvement in walking distance versus peak oxygen uptake in predicting prognosis after myocardial infarction and/or coronary artery bypass grafting in men. Am. J. Cardiol. 2008; 101: 1423–1427.

48. Espinosa Caliani S, Bravo Navas JC, Gómez-Doblas JJ, et al. Rehabilitación cardíaca postinfarto de miocardio en enfermos de bajo riesgo. Resultados de un programa de coordinación entre cardiología y atención primaria. Revista espanola de cardiologia 2004; 57: 53–59.

49. Lee JY, Ahn JM, Park DW, et al. Impact of exercise-based cardiac rehabilitation on long-term clinical outcomes in patients with left main coronary artery stenosis. European journal of preventive cardiology 2016; 23: 1804–1813.

50. Sunamura M, Ter Hoeve N, van den Berg-Emons, R. J. G., et al. Cardiac rehabilitation in patients with acute coronary syndrome with primary percutaneous coronary intervention is associated with improved 10-year survival. Eur Heart J Qual Care Clin Outcomes 2018; 4: 168–172.

51. Boulay P and Prud'homme D. Health-care consumption and recurrent myocardial infarction after 1 year of conventional treatment versus short- and long-term cardiac rehabilitation. Preventive medicine 2004; 38: 586–593.

52. Norris CM, Jensen LA, Galbraith PD, et al. Referral rate and outcomes of cardiac rehabilitation after cardiac catheterization in a large Canadian city. J Cardiopulm Rehabil 2004; 24: 392–400.

53. Kutner NG, Zhang R, Huang Y, et al. Cardiac rehabilitation and survival of dialysis patients after coronary bypass. Journal of the American Society of Nephrology JASN 2006; 17: 1175–1180.

54. Milani RV and Lavie CJ. Impact of cardiac rehabilitation on depression and its associated mortality. The American journal of medicine 2007; 120: 799–806.

55. Nielsen KM, Faergeman O, Foldspang A, et al. Cardiac rehabilitation: health characteristics and socio-economic status among those who do not attend. European journal of public health 2008; 18: 479–483.

56. Alter DA, Oh PI and Chong A. Relationship between cardiac rehabilitation and survival after acute cardiac hospitalization within a universal health care system. European journal of cardiovascular prevention and rehabilitation official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2009; 16: 102–113.

57. Hansen D, Dendale P, Leenders M, et al. Reduction of cardiovascular event rate: different effects of cardiac rehabilitation in CABG and PCI patients. Acta cardiologica 2009; 64: 639–644.

58. Suaya JA, Stason WB, Ades PA, et al. Cardiac rehabilitation and survival in older coronary patients. Journal of the American College of Cardiology 2009; 54: 25–33.

551 59. Junger C, Rauch B, Schneider S, et al. Effect of early short-term cardiac rehabilitation after acute ST-
552   elevation and non-ST-elevation myocardial infarction on 1-year mortality. Current medical research and
553   opinion 2010; 26: 803–811.

554 60. Goel K, Lennon RJ, Tilbury RT, et al. Impact of cardiac rehabilitation on mortality and cardiovascular
555   events after percutaneous coronary intervention in the community. Circulation 2011; 123: 2344–2352.

556 61. Martin BJ, Hauer T, Arena R, et al. Cardiac rehabilitation attendance and outcomes in coronary artery
557   disease patients. Circulation 2012; 126: 677–687.

558 62. Beauchamp A, Worcester M, Ng A, et al. Attendance at cardiac rehabilitation is associated with lower all-
559   cause mortality after 14 years of follow-up. Heart (British Cardiac Society) 2013; 99: 620–625.

560 63. Lee HY, Kim JH, Kim BO, et al. Regular exercise training reduces coronary restenosis after percutaneous
561   coronary intervention in patients with acute myocardial infarction. International journal of cardiology
562   2013; 167: 2617–2622.

563 64. Marzolini S, Leung YW, Alter DA, et al. Outcomes associated with cardiac rehabilitation participation in
564   patients with musculoskeletal comorbidities. European journal of physical and rehabilitation medicine
565   2013.

566 65. Pack QR, Goel K, Lahr BD, et al. Participation in cardiac rehabilitation and survival after coronary artery
567   bypass graft surgery: a community-based study. Circulation 2013; 128: 590–597.

568 66. Coll-Fernandez R, Coll R, Pascual T, et al. Cardiac rehabilitation and outcome in stable outpatients with
569   recent myocardial infarction. Archives of physical medicine and rehabilitation 2014; 95: 322–329.

570 67. Prince DZ, Sobolev M, Gao J, et al. Racial Disparities in Cardiac Rehabilitation Initiation and the Effect on
571   Survival. PM & R the journal of injury, function, and rehabilitation 2013.

572 68. Rauch B, Riemer T, Schwaab B, et al. Short-term comprehensive cardiac rehabilitation after AMI is
573   associated with reduced 1-year mortality: results from the OMEGA study. European journal of preventive
574   cardiology 2014; 21: 1060–1069.

575 69. Goel K, Pack QR, Lahr B, et al. Cardiac rehabilitation is associated with reduced long-term mortality in
576   patients undergoing combined heart valve and CABG surgery. European journal of preventive cardiology
577   2015; 22: 159–168.

578 70. Meurs M, Burger H, Riezen J, et al. The association between cardiac rehabilitation and mortality risk for
579   myocardial infarction patients with and without depressive symptoms: Journal of affective disorders;
580   188: 278–283.

581 71. Schlitt A, Wischmann P, Wienke A, et al. Rehabilitation in Patients With Coronary Heart Disease:
582   Participation and Its Effect on Prognosis. Dtsch Arztebl Int 2015; 112: 527–534.

583 72. Waldmann A, Katalinic A, Schwaab B, et al. The TeleGuard trial of additional telemedicine care in CAD
584   patients. 2 Morbidity and mortality after 12 months. Journal of telemedicine and telecare 2008; 14: 22–
585   26.
586 73. Barba R, Bisbe J, Pedrajas JNA, et al. Body mass index and outcome in patients with coronary,
587   cerebrovascular, or peripheral artery disease: findings from the FRENA registry. European journal of
588   cardiovascular prevention and rehabilitation official journal of the European Society of Cardiology,
589   Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2009;
590   16: 457–463.
591 74. Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect
592   of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial
593   infarction. Circulation 2010; 122: 2152–2159.
594 75. Spijkerman TA, van den Brink RHS, May JF, et al. Decreased impact of post-myocardial infarction
595   depression on cardiac prognosis? J Psychosom Res 2006; 61: 493–499.
596 76. van den Brink RHS, van Melle JP, Honig A, et al. Treatment of depression after myocardial infarction and
597   the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and
598   Depression-Intervention Trial (MIND-IT). American Heart Journal 2002; 144: 219–225.
599 77. Schulz S, Schlitt A, Lutze A, et al. The importance of genetic variants in TNFα for periodontal disease in a
600   cohort of coronary patients. J Clin Periodontol 2012; 39: 699–706.

601 Tables

602 Table 1. Newly identified studies selected for quantitative analysis; baseline study characteristics and overall results

Study Publication year Country	Study design	Population (P): a. Data sources b. Number of included participants (N) c. Index events d. Inclusion period e. Other inclusion criteria and characteristics f. Age (y, mean±SD or as stated) g. Gender (male, %)	Intervention (I): a. Number (n) b. Structured and multi-component CR (SMC-CR)? c. Start after index event d. Duration (time period and/or total number of CR sessions) e. Frequency (CR exercise sessions per wk) f. CR-setting	Control (C): a. Number (n) b. Treatment, characteristics	Outcome (O): a. Follow-up period b. Outcomes according to the CROS criteria (numbers according to table 1) c. Other outcomes not predefined by CROS II	Overall results, with respect to endpoints 1–10 as defined by CROS. Definitions are given at the end of the table*	Remarks
Espinosa Caliani S et al. 200448 Spain	pCCS	a. Institutional, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain. b. N=153 c. AMI d. not stated; after 1995 e. control group did not accept CR program f. 49.9±8.4 (CR+) 53.5±9.5 (no CR) g. 93.5	a. n=113 b. SMC-CR c. Immediately after discharge (phase I) d. 12 wk (phase II) at least 9 mo (phase III) e. n=3 (24 sessions) + educational talks, dietary and nutritional advice, psychological support (3mo, phase II). Maintenance phase III until 12 mo f. primary care centre (phase II, III)	a. n=40 b. CR non-attenders	a. 1 y1 y post AMI b. (10) c. Quality of life, exercise capacity, body mass index	Event rate (%CR+/noCR)) Endpoint 10 (angina, hospitalization, re-infarction, cardiac insufficiency and/or death): 6.7/ 6.7 (p=NS)	- Only patients with low-risk MI - CR by patients' decision - CR supervised by "family doctor" not by cardiologist - CR program accredited by Cardiology Spanish Society

Study / Country	Design	Methods	CR group	Control group	Outcomes	Results	Notes
Lee JY et al. 201649 Canada	pCCS	a. Data linkage: ASAN Medical Center-Left MAIN Revascularization registry (single-center retrospective database) b. N=3,040 c. mixed population: patients with unprotected LMCA stenosis >50% with subjective or objective ischemia; ACS (64.2%), silent ischemia (8%), stable AP (27.8%) d. 01/01/1995–31/12/2010 e. Patients treated with PCI (37.7%), CABG (49.1%) or medically (13.2%); end of follow-up 31/08/2014 f. 60.8±10.3 (CR+) 62.4±10.5 (no CR) g. 76.2 (CR+) 72.9 (no CR)	a. n=596 n=507 (matched pairs) b. SMC-CR c. Within 3 mo after index hospitalization (phase II) d. 3 mo (36 sessions) e. n=3 f. outpatient	a. n=2,444 n=507 (matched pairs) b. CR non-attenders	a. Mdn 7.3y (IQR, 4.4- 10.2y) b. (1),(2),(4),(5),(8) c. Risk factors' modification, exercise capacity, QoL, return to work, psychological results	Event rate (%CR+/noCR)) Endpoint 1: 13.3/ 18.5 Endpoint 2: 10.4/ 15.5 Endpoint 4: 3.0/ 6.7 p<0.001 for all Endpoint 5: 2.0/ 3.4 p=0.07 Endpoint 8: 7.3/ 10.9 p=0.006 HR (95% CI) after multivariate analysis Endpoint 1: 0.70 (0.49–1.00); p=0.05 Endpoint 2: 0.69 (0.48–0.97); p=0.03 Endpoints 4, 5, 8: p=NS HR (95% CI) propensity-matched pairs Endpoint 1: 0.62 (0.43–0.89); p=0.009 Endpoint 2: 0.54 (0.36–0.80); p=0.002 Endpoints 4, 5, 8: p=NS	- participation in CR was defined as attending at least one outpatient CR session (phase II) within 3 mo after index hospitalization
Aronov DM et al. 201730 Russia	RCT	a. Institutional Moscow Centre of Interventional Cardioangiology. b. N=36	a. n=18 b. SMC-CR (educational program + physical training) c. 2–8 wk after CABG (mean 7.8±1.6 wk)	a. n=18 b. CR non-attenders; only educational	a. 1 y b. (1), (6), (8), (10) c. Exercise and echiocardiography parameters, lipd levels, QoL,	Event (nr CR+/nr no CR) Endpoint 1: 0/0 Endpoint 6: 1/3 Endpoint 8: 1/1 Endpoint 10 (AP, MI, re-vascularization,	- publication in Russian language (translations received from Cochrane Russia

Study	Design	Intervention			Outcome measures	Follow-up	Results	Comments
		c. patients with IHD who had undergone CABG d. not stated; after 1995 e. -- f. 58.6±7.0 (CR+) 55.9±7.0 (no CR) g. 100	d. 4 mo e. n=3 f. monitored (medical supervision) or not-monitored (home based)	program available	AP attacks, return to work		hospitalization for IHD exacerbation): 2/7	and a private agency) - no statistical analyses of the results - CR had educational component only - contact to author not successful
Hautala AJ et al. 2017[33] Finland	RCT	a. EFEX-CARE (Effectiveness of Exercise Cardiac Rehabilitation) database of the Finnish Health care setting b. N=204 c. ACS d. 02/2011–05/2014 e. Exclusion criteria: NYHA ≥III, scheduled or emergency CABG, UA, severe peripheral atherosclerosis, diabetic retinopathy or neuropathy, inability to perform regular home-based exercises (i.e. severe musculoskeletal problems)	a. n=109 (drop-out, n=31) b. SMC-CR c. within 1 wk after hospital discharge d. 1 y e. n=4-5 (1 in hospital session per wk and home-based sessions for 6 mo; thereafter home based only) + information, motivation, education, social and vocational support f. outpatient	a. n=95 (drop-out, n=25) b. UC	a. 1 y b. (10) c. Health care costs, quality-adjusted life years, cost-effectiveness		Event rate (%CR+/no CR) Endpoint 10 after 1y: (combination of death, recurrent acute coronary event, or hospitalization for HF) 4.6/16.8, p=0.004	- Center-based CR under supervision of cardiologists and physiotherapists, all components of SMC-CR were available to most of the patients, no information about psychological support (information provided by the author)

		f. 60±11 (CR+), 62±9 (no CR) g. 73 (CR+), 71 (no CR)				
Doimo S et al. 2018[32] Italy	rCCS	a. Patients discharged from two tertiary hospitals b. N=1,280 c. mixed population; STEMI (n=378), NSTEMI (n=265), CABG with or without valve surgery (n=353) or planned PCI (n=284) d. 01/01/2009– 31/12/2010 e. Non-residents in the region or with severe non-cardiac comorbidities (i.e. end-stage tumors), dementia, or immobilized patients, were excluded from the CR group. 13% of eligible patients did not attend CR f. 68±11 (CR+), 66±12 (no CR) g. 68 (CR+), 75 (no CR)	a. n=839; STEMI (n=251), NSTEMI (n=162), CABG (n=243), PCI (n=183) b. SMC-CR c. 89 d (average) d. 5 mo (average) e. 1st part (10 sessions of 45min of cyclette training 2 times/wk for 5 wks); 2nd part (18 sessions of 45min of gym training 3 times/wk for 6wks) supervised by trained nurse and physiotherapist. Other components: Lifestyle counseling at every visit + nutritional advice once/mo + psychological support a. outpatient	a. n=441; STEMI (n=127), NSTEMI (n=103), CABG (n=110), PCI (n=101) b. CR non-attenders receiving all other components of CR	a. Mdn 82 mo (IQR 60 – 89 mo) b. PEP: (9) SEP: (1), (2), (6) c. effect of CR in various subgroups	Event rate (%CR+/no CR) Endpoint 1: 17/18 (p=0.861) Endpoint 2: 6/6 (p=0.623) Endpoint 6: 15/27 (p<0.001)) Endpoint 9: 18/30 (p<0.001)) HR (95% CI) Endpoint 9: 0.578 (0.432–0.773); p<0.001 Event rate, propensity matched analysis (%CR+/ no CR) Endpoint 1: 10/19 (p=0.002) Endpoint 2: 2/7 (p=0.008) Endpoint 6: 25/11 (p<0.001)) Endpoint 9: 29/13 (p<0.001))	- Group allocation by different hospitals - Multivariable regression model and propensity score matching analysis (covariates: age, sex, hypertension, LVEF, DM, smoking, CKD, dyslipidaemia, previous PCI, previous ACS, BB, ACEi/ARB, statins/ezetimibe) - statistical analysis does not address cardiovascular mortality adequately - 5-year composite endpoint as primary outcome (hospitalization for cardiovascular causes and cardiovascular mortality)

| Sunamura M et al. 2018[50] The Netherlands | rCCS | a. Patients from Erasmus Medical Centre (no CR), Rotterdam were propensity score matched with patients from Capri Cardiac Rehabilitation Cater, Rotterdam (CR+)
b. N=3,958
c. ACS followed by primary PCI
d. 2003 - 2011
e. Excluded: patients with cardiogenic shock (2.3%) and with early (within 60 d post-PCI) death (5.2%)
f. 59.0±9.9 (CR+), 58.8±11.83 (no CR)
g. 77 (CR+), 78 (no CR) | a. n=1,159
b. SMC-CR
c. Mdn 4-6 wk
d. 12 wk
e. n=2 (1.5h group exercise session). Other components: verbal and written instructions on how to deal with exercise, diet, smoking cessation, and stress management. Individual consultations with psychiatrist, psychologist, and social workers was available if necessary. Complete CR if attended at least 75% of the physical program
f. outpatient | a. n=1,159
b. no CR participants | a. Mdn 10 y 4-12 y (range)
b. (1)
c. Mortality rates of CR completion vs non-completion | Cumulative rates (% CR+/no CR)
Endpoint 1 at 5 y: 6.4/10.4
Endpoint 1 at 10 y: 14.7/23.5
HR (95% CI)
Endpoint 1 at 10y: (unadjusted) 0.56 (0.43-0.73)
(adjusted) 0.61 (0.46-0.81); p<0.001 | - Propensity score matching analysis 1:1 (covariates: age, sex, STEMI, current smoking, family history of CAD, HTN, hypercholesterolemia, DM, prior MI, prior history of PCI or CABG, proximal LAD lesion, socioeconomic status) |

603 Descriptive values of metric variables are given in mean or mean plus standard deviation (SD), if applicable. Other calculations are noted in the table. Mdn, median; N,
604 number of total population, n, number of subpopulation; d, days; wk, week(s); mo, month(s); y, year(s)

605 ACEi, angiotensin converting enzyme inhibitors; (A)MI, (acute) myocardial infarction; AP, angina pectoris; ARB, angiotensin receptor blockers; CABG, coronary artery bypass
606 grafting; BB, beta-blockers, ACEi/ARB CAD, coronary artery disease; CKD, chronic kidney disease; CR, cardiac rehabilitation; DM, diabetes mellitus; HF, heart failure; IHD,
607 ischemic heart disease; IQR, interquartile range; LAD, left anterior descending coronary artery; LMCA, left main coronary artery; LVEF, left ventricular ejection fraction; pCCS,
608 prospective controlled cohort trial; PCI, percutaneous coronary intervention; PEP, primary endpoint; QoL, quality of life; rCCS, retrospective controlled cohort trial; RCT,
609 randomized controlled trial; SEP, secondary endpoint; SMC-CR, structured and multi-component CR; (N) STEMI, (non) ST-elevation myocardial infarction; UC, usual care
610 including ambulatory supervision by family doctor and/or cardiologist, and may also include advise to exercise at home

611

612 Table 2. Summary of results

Outcome	Population (number of Studies)	Design (number of Studies)	Events/number of patients (CR)	Events/number of patients (control)	HR (95% CI)	OR (95% CI); pooling method	Heterogeneity: I2; tau2; p-value
Total mortality	ACS (11)	RCT (1)	82/903	84/910	1.01 (0.85-1.21)		NA
		pCCS (4)	NO/3,519	NO/2,063	0.37 (0.20-0.69)		18%; 0.092; p = 0.30
		rCCS (4)	NO/12,033	NO/24,266	0.64 (0.53-0.76)		33%;0.011; p = 0.22
		rCCS (2)	109/2,901	241/1,846		0.20 (0.08-0.48); MH	60%; 0.288; p = 0.11
	CABG (6)	RCT (1)	0/18	0/18		1.00 (0.02-53.12); NA	NA
		pCCS (1)	1/149	5/89		0.11 (0.01-0.99); NA	NA
		rCCS (4)	NO/5,109	NO/7,889	0.62 (0.54-0.70)		0%; 0; p = 0.71
	Mixed (10)	pCCS (2)	254/3,407	398/2,939	0.66 (0.55-0.79)		0%; 0; p = 0.72
		rCCS (5)	NO/2,606	NO/3,577	0.52 (0.36-0.77)		84%;0.145; p < 0.01
		rCCS (3)	1,700/71,674	3,806/71,160		0.68 (0.34-1.37); NA	94%; 0.339; p < 0.01
Cardiovascular mortality	ACS (2)	pCCS (1)	18/2,505	32/1,042	0.44 (0.24-0.82)		NA
		pCCS (1)	0/37	1/37		0.32 (0.01-8.23); NA	NA
	CABG (2)	pCCS (1)	0/18	0/18		1.00 (0.02-53.12); NA	NA
		rCCS (1)	NO/527	NO/4,747	0.64 (0.51-0.81)		NA
	Mixed (3)	pCCS (1)	37/507	75/507	0.54 (0.36-0.80)		NA
		rCCS (1)	34/719	46/719	0.67 (0.44-1.03)		NA
		rCCS (1)	48/839	28/441		0.90 (0.55-1.45); NA	NA
MACCE	ACS (2)	pCCS (1)	81/2,376	81/971	0.55 (0.39-0.77)		NA
		rCCS (1)	212/2,756	281/1,791		0.70 (0.35-1.40); NA	NA
	Mixed (1)	rCCS (1)	158/785	206/1,224	0.85 (0.74-0.98)		NA
Non-fatal myocardial infarction	ACS (3)	RCT (1)	7/162	8/115		0.60 (0.21-1.72); NA	NA
		pCCS (1)	43/2,362	27/946	0.75 (0.45-1.26)		NA
		pCCS (1)	0/37	0/37		1.00 (0.02-51.73); NA	NA

Outcome	Indication	Study	CR	Control	Effect estimate	Effect estimate (method)	Heterogeneity
	CABG (1)	pCCS (1)	3/343	13/334		0.22 (0.06-0.77); NA	NA
	Mixed (3)	pCCS (1)	15/507	23/507	0.65 (0.34-1.26)		NA
		rCCS (1)	NO/785	NO/1,224	1.01 (0.74-1.37)		NA
		rCCS (1)	14/795	26/679		0.45 (0.23-0.87); NA	NA
Non-fatal stroke	ACS (2)	RCT (1)	0/162	1/115		0.23 (0.01-5.81); NA	NA
		pCCS (1)	10/2,364	13/954	0.35 (0.14-0.85)		NA
	Mixed (1)	pCCS (1)	8/507	13/507	0.92 (0.24-3.52)		NA
Hospital readmission for any reason	ACS (3)	pCCS (2)	794/2,447	351/1,035		0.96 (0.81-1.13); IV	0%; 0; p = 0.32
		rCCS (1)	NO/878	NO/824	1.00 (0.82-1.22)		NA
	CABG (1)	RCT (1)	3/18	1/18		3.40 (0.32-36.27); NA	NA
	Mixed (2)	pCCS (1)	NO/2,900	NO/2,432	0.77 (0.71-0.84)		NA
		rCCS (1)	253/795	258/679		0.76 (0.61-0.94); NA	NA
Unplanned readmission for any cardiovascular event	ACS (2)	RCT (1)	23/162	16/115		1.02 (0.51-2.04); NA	NA
		pCCS (1)	17/74	20/54		0.51 (0.23-1.10); NA	NA
	Mixed (2)	pCCS (1)	32/2,900	109/2,432	0.68 (0.55-0.84)		NA
		rCCS (1)	122/839	119/441		0.46 (0.35-0.61); NA	NA
Unplanned coronary revascularization	ACS (1)	pCCS (1)	4/69	7/72		0.57 (0.16-2.05); NA	NA
	CABG (1)	pCCS (1)	44/343	49/334		0.86 (0.55-1.33); NA	NA
	Mixed (1)	pCCS (1)	44/507	33/507	1.38 (0.88-2.16)		NA
		rCCS (1)	33/795	37/679		0.75 (0.46-1.22); NA	NA
Cardiovascular mortality and readmission	ACS (1)	pCCS (1)	0/74	4/54		0.08 (0.00-1.43); NA	NA
	Mixed (1)	rCCS (1)	155/839	133/441	0.58 (0.43-0.77)		NA
Combined endpoints	ACS (8)	RCT (1)	5/109	16/95	0.26 (0.09-0.73)		NA
		RCT (1)	24/162	25/115		0.63 (0.34-1.15); NA	NA
		pCCS (1)	NO/521	NO/522	0.65 (0.30-1.41)		NA
		pCCS (4)	47/620	69/567		0.58 (0.33-1.00); MH	21%; 0.080; p = 0.28
		rCCS (1)	183/2,756	263/1,791		0.41 (0.34-0.50); NA	NA
	CABG (2)	RCT (1)	2/18	7/18		0.20 (0.03-1.13); NA	NA
		pCCS (1)	44/343	68/334		0.58 (0.38-0.87); NA	NA
	Mixed (2)	rCCS (1)	NO/785	NO/1,224	0.77 (0.65-0.91)		NA
		rCCS (1)	259/795	263/679		0.73 (0.59-0.91); NA	NA

613 ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; NO, sum of events has not been calculated, if one study of a specific subgroup did not report the
614 number of events; MH, Mantel-Haenszel pooling; NA, not applicable; IV, inverse variance pooling; RCT, randomised controlled trial; rCCS, retrospective controlled cohort
615 study; pCCS, prospective controlled cohort study; HR, hazard ratio; CI, confidence interval; OR, odds ratio.

616

Table 3a. Quality evaluation of cohort studies included into meta-analysis[20,21]

Study	Basic design	NOS, sum of positive adjudications	Reporting of CR-characteristics Ŧ	Specific actions to select and compare the groups *	Were groups formed by: Time differences?	Location differences?	Health care decision makers?	Patient's preferences	On the basis of outcome?	Protocol pre-specifying study outcomes?	Was the intervention's effect a pre-specified study objective? †	Were outcomes, as specified in the CROS protocol, measured and analyzed? †	Consort flow diagram available?	Potential selection bias?	Potential reporting bias (selectively reporting outcomes according to statistical significance?	Potential reporting bias (selectively reporting multiple adjusting	Management of confounding (design stage) General control for confounding	Have selection criteria for potential confounding domains been described?	Did researchers pre-specify and calculate confounding domains as specified by CROS? ‡	Adjustment for confounding? (analysis)	Method (adjustment for confounding) §
Boulay 200451	R	3	+	1	Y	N?	Y?	Y?	N	Y?	Y	4,7	N	Y	N	NA	Y	N	1,2,7	N	NA
Norris 200452	R	8	(+)	2	N	N	Y	N?	N	Y?	Y	1	N	Y	N	N	Y	Y	1,2,4-7	Y	a,c,d
Kutner 200653	R	7	↓	3	N	N	NC	NC	N	Y?	Y	1,2	N	Y	N	N	Y	Y	1,2,4,6	Y	a,d
Milani 200754	R	6	+	4	N	N	Y	NC	N	Y	Y	1	N	N	N	N	Y	N	1,2,4,7	Y	a,d
Nielsen 200855	R	8	+	5	N	N	NC	NC	N	Y?	Y	1,4	N	Y	N	N	Y	N	1,2	Y	a
Alter 200956	R	8	+	6	N	N	Y	Y	N	Y?	Y	1	Y	Y	N	N	Y	Y	1,2,4,6	Y	a,d,e
Hansen 200957	P	6	+	7	N	Y	Y	NC	N	N	Y	1,4,8,10	N	Y?	N	N	Y	N	1,2-4,8	Y	a,d
Suaya 200958	R	7	(+)	6	N	N	Y?	Y?	N	NC	Y	1	N	Y	N	N	Y	Y	1,2,4-7	Y	a,b,d
Jünger 201059	R	7	(+)	8	N	N	Y	Y	N	Y	Y	1,3,10	Y	Y	N	N	Y	N	1-8	Y	a,c,d
Goel 201160	R	7	(+)	6,15	N	N	Y	Y	N	Y?	Y	1,2,4,8,10	N	Y	N	N	Y	Y	1-8	Y	b,c,d
Kim 201128	P	4	(+)	9	N	N	NC	Y	N	NC	Y?	1,6,8,10	N	NC	NC	NA	Y	N	1,2,4,7	N	NA
Schwaab 201131	R	6	(+)	10	N	NC	Y	Y	N	NC	Y?	1,4,6,8	N	NC	N	N	Y	N	1,2,7	Y	a
Martin 201261	P	7	(+)	11	N	N	Y	Y?	N	Y?	Y?	1,6,7	Y	Y	N	N	Y	NC	1-8	Y	a,b
Beauchamp 201362	R	7	(+)	12	N	N	Y	Y	N	NC	N?	1	N	N	N	NC	N	N	1,2,4	Y	a
Lee 201363	P	8	(+)	13	N	N	Y	Y	N	NC	Y	2,4,10	N	N	N?	N	N	N	N	N	NA
Marzolini 201364	P	8	↓	14	N	N	Y	Y	N	Y	Y?	1,10	Y	Y	N	N	Y	Y	1-4	Y	a,c
Pack 201365	R	7	+	15	N	N	Y	Y	N	Y?	Y	1	N	N	N	N	Y	Y	1-7	Y	a-d
Coll-Fernandez 201466	P	8	↓	16	N	N	Y	Y?	N	NC	Y	1,10	N	N	N	N	Y	Y	1-4,8	Y	a,d

Study																						
Prince 201467	R	6	↓	17	N	N	Y	Y	N	Y?	Y	1	N	N	N	N	Y	N	1,2	Y	a
Rauch 201468	P	8	+	18	N	N	Y	Y	N	Y	Y	1-6,8	Y	Y	N	N	Y	Y	1-8	Y	a,c,d
Goel 201369	R	7	(+)	15	N	N	Y	Y	N	Y?	Y	1	N	N	N	N	Y	Y	1-3,5	Y	a,c,d
De Vries 201527	R	7	+	19	N	N	Y	Y	N	Y	Y	1	Y	N	N	N	Y	Y	1,2,4,5,7	Y	a,c,d
Meurs 201570	R	5	(+)	20	N	N	Y	Y	N	Y	Y	1,6	N	Y	N	N	Y	Y	1,2,6,7	Y	a,d
Schlitt 201571	R	4	(+)	21	N	N	Y	Y	N	NC	Y	1	N	Y	N	NC	Y	N	1-7	Y	a,d
Lee 201649	P	7	+	22	N	N	Y	NC	N	Y?	Y	1,4,5,8	Y	N	N	N	Y	N	N	Y	a,b
Espinosa Caliani 200448	P	6	+	23	N	NC	NC	Y	N	NC	NC	10	N	N	N	N	N	N	N	N	NA
Doimo 201832	R	5	+	6, 24	N	Y	NC	NC	N	Y?	Y	1,7,9,10	N	N	N	N	Y	N	1-4,6,7	Y	a,d
Sunamura 201850	R	7	+	7	N	NC	NC	NC	N	NC	Y	1	N	N	N	N	Y	N	1-4,6	Y	a-d

618 ₸ Reporting of CR-characteristics: +, sufficient; (+), information obtained by author or other sources; ↓, information limited

619 * specific actions to compare groups: (1) prospectively evaluated intervention group versus retrospectively evaluated control group; (2) linkage of Canadian APPROACH and
620 NACPR registry; (3) data extracted from the United States renal data System, USRDS; (4) retrospective identification of groups by questionnaires within a predefined study
621 cohort; (5) retrospective identification of groups in a population surviving AMI for at least 30 d; (6) retrospective evaluation and formation of matched pairs; (7) groups were
622 formed by two hospitals following different CR referral policies; (8) retrospective identification of groups by questionnaires and personal contact to relatives of deceased
623 patients; (9) groups were formed prospectively according to predefined inclusion and exclusion criteria; (10) retrospective definition of the study groups out of an
624 independent pre-existing study cohort on the basis of medical records;72 (11) propensity score matching; (12) retrospective evaluation of a pre-existing cohort of another
625 study evaluating CR attendance after automatic referral; (13) predefinition of inclusion and exclusion criteria, but final group formation by patient`s preferences and health
626 care decision makers; (14) selection of CAD-patients with musculoskeletal disease in addition. (15) retrospective definition of the groups; CR+ group was defined as attending
627 at least one session within 6 mo after the index event; (16) prospective definition of the groups out of the FRENA registry;73 (17) patients referred to CR but not attending
628 served as control; (18) groups were pre-specified from the OMEGA-trial cohort;74 (19) 180 days survival after index event required; (20) study population has been extracted
629 from two pre-existent studies (DepeMI, MIND-IT);75,76 (21) retrospective recruitment of study population from two previous RCT not investigating CR or prognostic CAD
630 outcomes;71,77 (22) data extracted from ASAN Medical Center-Left MAIN Revascularization registry and ASAN Medical Center cardiac rehabilitation database; (23) control
631 group was formed of patients who did not accept CR program; (24) matching pairs from the Capri Cardiac Rehabilitation database and Erasmus Medical Centre database
632 (control)

633 † Outcomes under investigation: the numbers refer to the predefined outcomes as outlined in Table 1.

634 ‡ Confounding domains as specified by CROS: 1, age; 2, sex; 3, smoker; 4, diabetes; 5, history of stroke; 6, history of acute myocardial infarction; 7, reduced left ventricular
635 ejection fraction; 8, acute/early
636 percutaneous coronary intervention during acute myocardial infarction.

637 § Biometrical methods to manage confounding: (a) multivariable regression analysis; (b) propensity score matching; (c) propensity score-adjusted multivariable regression
638 analysis; (d) confounders described; (e) retrospective matched pairs. Adjusting only for age and gender has been regarded as insufficient for the limitation of confounding.
639 APPROACH, Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease; NACRP, Northern Alberta Cardiac Rehabilitation Program; FRENA, Risk Factors
640 and Arterial Disease registry (Factores de Riesgo y ENfermedad Arterial); OMEGA, Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty

641 Acids on Top of Modern Guideline-Adjusted Therapy after Myocardial Infarction; DepreMI, Depression after Myocardial Infarction study; MIND-IT, Myocardial Infarction
642 and Depression Intervention Trial.
643 R, retrospective cohort control study; P, prospective cohort control study; Y, yes; Y?, probably yes; N, no; N?, probably no; NC, not clear, not reported; NA, not applicable;
644 green → adjudication is in favor to reliability of results and reporting;
645 yellow → item potentially increases risk of limited reliability of results and reporting;
646 red → item increases risk of reliability of results and reporting.
647

648

649　Table 3b. Quality evaluation of randomised controlled trials included into meta-analysis (according to the Cochrane risk of bias table)

Risk	West 201214	Aronov 201730	Hautala 201733
Under-powering	High risk	High risk	Unclear risk
Selection bias	Unclear risk	Unclear risk	Low risk
Random sequence selection bias	Unclear risk	High risk	Low risk
Allocation concealment	Low risk	High risk	Unclear risk
Confounding variables	Unclear risk	High risk	Low risk
Performance bias	Low risk	Unclear risk	Low risk
Detection bias	Low risk	Unclear risk	Low risk
Attrition bias (incomplete outcome data)	Low risk	Low risk	Low risk
Groups balanced at baseline	Low risk	Unclear risk	Low risk
Groups not receiving the same baseline treatment	Unclear risk	Low risk	Low risk
Intention to treat analysis	Low risk	Low risk	Low risk
Reporting bias	Low risk	Low risk	Low risk
Comments	Low recruitment (22.5% CR arm; 22.7% control arm), study participation influenced by patient`s preferences, random sequence generation is not reported, per protocol centrally organized randomization and blinded with respect to baseline characteristics, confirmation of exposure sufficient, CR status has been blinded before outcome assessment, follow-up reporting was completed in 95% of surviving patients, baseline treatment with respect to medication and medical supervision has to be assumed; control group may also have received life style support to a variable extend	No primary endpoint defined; no pre-estimation of sample sizes and effect sizes were described with respect to any endpoint measured), exclusively low risk patients, no randomization method described, potential confounding variables were not assessed, no allocation concealment, interactions between the study groups confounding performance cannot be excluded, Baseline values were presented in a descriptive way without statistical evaluation. At least in n=3 relevant clinical characteristics a balance between groups was not achieved	Primary endpoint: Cost / quality-adjusted life year of a cardiac patient (QALY) Secondary endpoint: Major Adverse Cardiac Event (MACE) Statistical power of the study has not been reported with respect to either of the presented endpoints

650　green → adjudication is in favour to reliability of results and reporting; yellow → item potentially increases risk of limited reliability of results and reporting; red → item
651　increases risk of reliability of results and reporting.

652

653   Figure legends

654   Figure 1. Study selection flow chart

655   a Other reasons PS level: reviews, letters, study protocol, only abstract available, b Other reasons FTE level: referral
656   only, referral only, no information about CR enrollment and adherence available. ICTRP: International Clinical Trials
657   Registry Platform; PS: primary selection of extracted studies; FTE: full-text evaluation; SSE: structured study
658   evaluation and quality analysis according to the checklist of methodological issues on non-randomized studies.20

659   Figure 2. Analysis of total mortality

660   Forest plots presenting the evaluation of the endpoint "total mortality". HR, Hazard ratio; OR, Odds ratio; MH,
661   Mantel-Haenszel pooling method; CR, cardiac rehabilitation; no CR, no cardiac rehabilitation (control); CI, confidence
662   interval; Events, number of events in the evaluated group; Total, number of patients in the evaluated group; Start
663   (w), start of cardiac rehabilitation after hospital discharge in weeks; Follow-up, follow-up in years.